Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.53 USD
-0.27 (-4.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.49 -0.04 (-0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RXRX 5.53 -0.27(-4.66%)
Will RXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Other News for RXRX
Recursion Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $19. ...
Recursion Sets $100 Million Partnership Goal by 202
Recursion Pharmaceuticals (RXRX) Exceeds Revenue Expectations in Q2
Recursion Pharmaceuticals (RXRX) Reports Mixed Q2 Results with Revenue Beat
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | RXRX ...